GAD1 and prostate carcinoma: Importantly, we found a significant correlation between the GAD1 pathway and KEGG_DRUG_METABOLISM_OTHER_ENZYMES [normalized enrichment score (NES) = 1.599, p.adj = 0.039, false discovery rate (FDR) = 0.034], which predicted that GAD1 might influence the metabolism of docetaxel or enzalutamide to develop drug resistance in prostate cancer (Fig. 6B).